ScholarLens Back to search
2010•Guide of China MedicineRequires access

Clinical Comparative Sbservation of Propafenone and Verapamil in Treatment of Paroxysmal Supraventricular Tachycardia

YE Shao-wu

Open publisher page 0 citations

Abstract

Objective Investigate the clinical effi cacy of propafenone and verapamil in treatment of paroxysmal supraventricular tachycardia. Methods In this paper, using propafenone and verapamil to treat paroxysmal supraventricular tachycardia patients, and comparing their clinical effi cacy. Results The effective rate and the total effective rate of propafenone group were signifi cantly higher than that of verapamil group (P0.05). The incidence of adverse reactions in propafenone group was signifi cantly lower than that of verapamil group (P0.05). Conclusion Propafenone had good clinical effi cacy and little adverse reactions that were both better than verapamil. So, propafenone can be used as the fi rst choice drug in the treatment of PSVT in clinical.

About this research paper

What this paper is about

Objective Investigate the clinical effi cacy of propafenone and verapamil in treatment of paroxysmal supraventricular tachycardia. Methods In this paper, using propafenone and verapamil to treat paroxysmal supraventricular tachycardia patients, and comparing their clinical effi cacy. Results The effective rate and the total effective rate of propafenone group were signifi cantly higher than that of verapamil group (P0.05). The incidence of adverse reactions in propafenone group was signifi cantly lower than that of verapamil group (P0.05). Conclusion Propafenone had good clinical effi cacy and little adverse reactions that were both better than verapamil. So, propafenone can be used as the fi rst choice drug in the treatment of PSVT in clinical.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective Investigate the clinical effi cacy of propafenone and verapamil in treatment of paroxysmal supraventricular tachycardia. Methods In this paper, using propafenone and verapamil to treat paroxysmal supraventricular tachycardia patients, and comparing their clinical effi cacy. Results The effective rate and the total effective rate of propafenone group were signifi cantly higher than that of verapamil group (P0.05). The incidence of adverse reactions in propafenone group was signifi cantly lower than that of verapamil group (P0.05). Conclusion Propafenone had good clinical effi cacy and little adverse reactions that were both better than verapamil. So, propafenone can be used as the fi rst choice drug in the treatment of PSVT in clinical.

Key concepts: Propafenone, Medicine, Verapamil, Paroxysmal supraventricular tachycardia, Supraventricular tachycardia, Internal medicine, Supraventricular arrhythmia, Cardiology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Comparative Sbservation of Propafenone and Verapamil in Treatment of Paroxysmal Supraventricular Tachycardia — Research Paper | ScholarLens